XAIRNCMHealthcare·Medical Devices#120 in industry

Beyond Air, Inc.

-63.9% · 90d

$0.49

-0.02 (-4.49%)

After-Hours $0.50(+0.01)

News

(1)

April 2026

Apr 1, 20263 weeks ago8-KHealthcare

Beyond Air, Inc. — 8-K Filing

XAIRBeyond Air, Inc.

# 🧾 What This Document Is This is an **8-K filing**, which is a report companies file with the SEC to announce major, shareholder-impacting news. In this case, it contains two parts: 1. The official legal **Separation Agreement** with the departing CEO. 2. A **Press Release** announcing the leade

Read summaryView on SEC EDGAR

Key Data

Market Cap$5.1M

Open$0.53

Prev Close$0.51

Day Range$0.48 – $0.53

52W Range$0.43 – $5.84

Volume190,660

P/E (TTM)—

EPS$-4.47

Dividend Yield—

Beta0.53

Revenue Growth104.70%

Price Target$8.67(+1679.2%)

Next Earnings2026-02-13

Analyst Ratings

Strong Buy4 analysts

Buy 3Hold 1Sell 0

About

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Healthcare · Medical Devices

61 employees

www.beyondair.net